explore -WSS

explore

author：explore 2025-10-03 00:07:43 - browse：16

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： STAT's guide to the next generation of CAR

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

340B reform proposal comes out of Senate working group

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Adopting new red light myopia treatments may be short

Disclosing genetic information: not as worrisome as once feared

What’s missing from the debate over nursing home staff minimums

hotspot

explore

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD: Venture capital, Gilead, and more M&A

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Novavax promises a turnaround & Lilly roils the obesity market

Top private equity targets in 2023: cardiology, clinical trials, lasers

What does generative AI mean for health care? We asked experts

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

How to save PrEP access — and even expand it

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

hotspot

Cano Health’s bankruptcy is a warning for Medicare Advantage

The story of mRNA: From a loose idea to a tool that may help curb Covid

#NeedHerScience: shining a light on gender disparities in medicine

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

What would happen to your eyes if you looked at the solar eclipse?

The Biogen Aduhelm mess could happen again

explore

Wikipedia

Wikipedia

leisure time